167 related articles for article (PubMed ID: 31090170)
1. Potential Effects of Telbivudine Versus Entecavir on Renal Function in Patients With Chronic Hepatitis B Virus Receiving Glucocorticoids Therapy.
Liu B; Shen B; Mei M; Li L; Wang X; Zhao H
Ther Apher Dial; 2020 Feb; 24(1):56-63. PubMed ID: 31090170
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
Pan HY; Pan HY; Song WY; Zheng W; Tong YX; Yang DH; Dai YN; Chen MJ; Wang MS; Huang YC; Zhang JJ; Huang HJ
J Viral Hepat; 2017 Nov; 24 Suppl 1():29-35. PubMed ID: 29082652
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine.
Cai S; Cao J; Yu T; Xia M; Peng J
Medicine (Baltimore); 2017 Jun; 96(22):e7021. PubMed ID: 28562554
[TBL] [Abstract][Full Text] [Related]
4. Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis.
Su QM; Ye XG
World J Gastroenterol; 2012 Nov; 18(43):6290-301. PubMed ID: 23180951
[TBL] [Abstract][Full Text] [Related]
5. Comparison of efficacy and renal safety of telbivudine and entecavir in treatment-naive elderly patients with chronic hepatitis B.
Law ST; Lee MK; Li KK; Mok CK
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):193-8. PubMed ID: 26587867
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
Lu JJ; Liu K; Ma YJ; Wang J; Chen EQ; Tang H
J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections.
Gan W; Li J; Zhang C; Chen X; Lin C; Gao Z
BMC Infect Dis; 2020 Dec; 20(1):931. PubMed ID: 33287722
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of telbivudine and entecavir against virus reactivation in HBeAg-patients undergoing chemotherapy.
Chen CJ; Yu HC; Chang CW; Bair MJ; Lin CC; Lin YS; Cai ZS; Chen MJ
Medicine (Baltimore); 2020 May; 99(22):e20330. PubMed ID: 32481407
[TBL] [Abstract][Full Text] [Related]
9. Comparison of clinical efficacy and renal safety of telbivudine and entecavir in chronic hepatitis B patients receiving cytotoxic chemotherapy.
Law ST; Lee MK; Lee AS; Tung Y; Li KK
J Dig Dis; 2016 May; 17(5):325-33. PubMed ID: 27085094
[TBL] [Abstract][Full Text] [Related]
10. [Compare the effect of combined therapy between telbivudine plus adefovir dipivoxil and lamivudine plus adefovir dipivoxil corresponding to renal function in patients with hepatitis B virus infection].
Xu J; Bao L; Wang Y; Yang L; Li WT; Zhao ZH; Li Y
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):288-293. PubMed ID: 29996341
[No Abstract] [Full Text] [Related]
11. Telbivudine and adefovir dipivoxil combination therapy improves renal function in patients with chronic hepatitis B: A STROBE-compliant article.
Xu Y; Nie ZW
Medicine (Baltimore); 2018 Nov; 97(48):e13430. PubMed ID: 30508954
[TBL] [Abstract][Full Text] [Related]
12. Effects of entecavir, tenofovir and telbivudine treatment on renal functions in chronic hepatitis B patients.
Kara AV; Yıldırım Y; Ozcicek F; Aldemir MN; Arslan Y; Bayan K; Çelen MK
Acta Gastroenterol Belg; 2019; 82(2):273-277. PubMed ID: 31314188
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life.
Luo J; Li X; Wu Y; Lin G; Pang Y; Zhang X; Ao Y; Du Z; Zhao Z; Chong Y
Int J Med Sci; 2013; 10(4):427-33. PubMed ID: 23471472
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy.
Wang ML; Chen EQ; Zhang DM; Du LY; Yan LB; Zhou TY; Lei XZ; Lei BJ; Lu JJ; Liao J; Tang H
J Viral Hepat; 2017 Nov; 24 Suppl 1():21-28. PubMed ID: 29082645
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
Luo XD; Chen XF; Zhou Y; Chen XP
J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
[TBL] [Abstract][Full Text] [Related]
16. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
[TBL] [Abstract][Full Text] [Related]
17. A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China.
Zhang Y; Hu P; Qi X; Ren H; Mao RC; Zhang JM
Clin Microbiol Infect; 2016 Mar; 22(3):287.e1-9. PubMed ID: 26548508
[TBL] [Abstract][Full Text] [Related]
18. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a].
Luo XD; Chen XP; Chen R; Chen XF; Huang J
Zhonghua Gan Zang Bing Za Zhi; 2016 Apr; 24(4):241-5. PubMed ID: 27470620
[TBL] [Abstract][Full Text] [Related]
20. Comparison of telbivudine and entecavir on the change of off- treatment eGFR after 3 years of treatment in non-cirrhotic chronic hepatitis B patients.
Lin YS; Shih SC; Wang HY; Lin CC; Chang CW; Chen MJ
BMC Gastroenterol; 2017 Jan; 17(1):22. PubMed ID: 28137301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
